Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950445 | 0.94 | MEN1 (0.40) | MEN1KMT2AAGTR2CHRM4KDM4E | |
| SCHEMBL12231325 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2ASIGMAR1KDM4EGAA | |
| SCHEMBL22368009 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2ASIGMAR1KDM4EGAA | |
| SCHEMBL15475235 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2ASIGMAR1KDM4EGAA | |
| SCHEMBL12231324 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2ASIGMAR1KDM4EGAA | |
| SCHEMBL1358169 | 0.92 | ALDH1A1 (0.40) | MEN1KMT2ASIGMAR1KDM4EGAA | |
| SCHEMBL13823122 | 0.86 | KMT2A (0.35) | MEN1KMT2AAGTR2SIGMAR1KDM4E | |
| SCHEMBL10126869 | 0.81 | RAB9A (0.36) | MEN1KMT2ACHRM4 | |
| SCHEMBL13624814 | 0.81 | RAB9A (0.36) | MEN1KMT2ACHRM4 | |
| SCHEMBL12018913 | 0.81 | RAB9A (0.36) | MEN1KMT2ACHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382905-B2 | Immunomodulation by IAP inhibitors | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| EP-2698158-B1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| US-20200345714-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | disclosed |
| US-10329626-B2 | NOL3 is a predictor of patient outcome | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170368047-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2017-12-28 | — | — | US | disclosed |
| US-9750729-B2 | Immunomodulation by IAP inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750729-B2 | Immunomodulation by IAP inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170101688-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | DANA-FARBER CANCER INSTITUTE (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170101688-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | DANA-FARBER CANCER INSTITUTE (US) | 2017-04-13 | — | — | US | disclosed |
| US-9533980-B2 | NOL3 is a predictor of patient outcome | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110135691-A1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG | 2011-06-09 | — | — | US | disclosed |
| US-20110135691-A1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG | 2011-06-09 | — | — | US | disclosed |
| US-20100179163-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | DANA-FARBER CANCER INSTITUTE, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179163-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | DANA-FARBER CANCER INSTITUTE, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | MEN1 2598/4885KMT2A 4593/4885AGTR2 2111/4885 |
| US-20170368047-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | MEN1 949/4885KMT2A 3118/4885AGTR2 1799/4885 |
| US-11382905-B2 | Immunomodulation by IAP inhibitors | BIRC2, BIRC3, BIRC5 | MEN1 949/4885KMT2A 3118/4885AGTR2 1799/4885 |
| US-20170101688-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | MORF4L1, NOS3, NOS1 | MEN1 1583/4885KMT2A 2131/4885AGTR2 4317/4885 |
| US-20110281875-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | MEN1 2365/4885KMT2A 4431/4885AGTR2 2390/4885 |
| US-20200345714-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | MEN1 949/4885KMT2A 3118/4885AGTR2 1799/4885 |
| US-10329626-B2 | NOL3 is a predictor of patient outcome | MORF4L1, NOS3, NOS1 | MEN1 1583/4885KMT2A 2131/4885AGTR2 4317/4885 |
| US-20100179163-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | MORF4L1, NOS3, NOS1 | MEN1 1583/4885KMT2A 2131/4885AGTR2 4317/4885 |
| US-20110135691-A1 | IMMUNOMODULATION BY IAP INHIBITORS | BIRC2, BIRC3, BIRC5 | MEN1 949/4885KMT2A 3118/4885AGTR2 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.